|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, we observed that amplification of FBXW7 in wild-type p53 tumors reduced the survival of patients with breast cancer.
|
31337255 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer.
|
31351478 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
This new regulatory mechanism of MTDH by FBXW7 represents a new pathway for malignant phenotype turnover in human breast cancer.
|
29534580 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the contribution of Ago2, the only human Ago protein endowed with nuclease activity, to the function of tumor-suppressor miR-145-5p in breast cancer (BC).
|
30622242 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we show that Fbxw7 is essential for the maintenance of breast cancer dormancy.
|
30830867 |
2019 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Molecular mechanisms involved in the relapse of T-cell acute lymphoblastic leukemia (T-ALL) are not fully understood, although activating NOTCH1 signaling due to NOTCH1/FBXW7 alterations is a major oncogenic driver.
|
30387229 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
FBXW7 is underexpressed in breast cancer tissues and cell lines, and is an independent positive factor for the overall survival rate of patients with breast cancer.
|
30365154 |
2018 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that NOTCH1/FBXW7 hotspot-mutated T-ALL cases had better response to ALL BFM-95 protocol.
|
29200162 |
2018 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we find that levels of STYX and FBXW7 are anti-correlated in breast cancer patients, which affects disease prognosis.
|
28007894 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the effect of miR-32 on cell proliferation, migration and apoptosis and to determine the functional connection between miR-32 and FBXW7 in breast cancer.
|
28149200 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis of the clinical characteristics and prognostic relevance of NOTCH1 and FBXW7 mutation in T-cell acute lymphoblastic leukemia.
|
29029518 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We investigated the role of FBXW7 and their substrates MCL1 and PLK1 in regulating the apoptotic response to paclitaxel treatment in breast cancer cells and their expression in breast cancer tissues.
|
27409838 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
|
27022068 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Ten years ago gene-expression profiles were introduced to aid adjuvant chemotherapy decision making in breast cancer.
|
27062369 |
2016 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations.
|
26220040 |
2016 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using an integrative approach combining genomic and transcriptomic data, we molecularly characterized 30 pediatric T-ALLs and identified common recurrent T-ALL targets such as FBXW7, JAK1, JAK3, PHF6, KDM6A and NOTCH1 as well as novel candidate T-ALL driver mutations including the p.R35L missense mutation in splicesome factor U2AF1 found in 3 patients and loss of function mutations in the X-linked tumor suppressor genes MED12 (frameshit mutation p.V167fs, splice site mutation g.chrX:70339329T>C, missense mutation p.R1989H) and USP9X (nonsense mutation p.Q117*).
|
27602765 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
F-box and WD repeat domain-containing 7 (FBXW7) is a potent tumor suppressor in human cancers including breast cancer, colorectal cancer, gastric cancer and hepatocellular carcinoma.
|
25622249 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
|
25721604 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
FBXW7 mutations were detected in 5 of the 50 (10%) T-ALL patients.
|
25493453 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study revealed differences in the mutational profiles of pediatric and adult T-ALL and suggests mutant FBXW7 as an independent prognostic indicator for inferior survival in pediatric T-ALL.
|
26341754 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In T-cell acute lymphoblastic leukemia (T-ALL), elevated MYB levels can arise directly through T-cell receptor-mediated MYB translocations, genomic MYB duplications or enhanced TAL1 complex binding at the MYB locus or indirectly through the TAL1/miR-223/FBXW7 regulatory axis.
|
25231743 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activation of the NOTCH pathway occurs commonly in T acute lymphoblastic leukemia (T-ALL) mainly due to mutations in NOTCH1 or alterations in FBW7 and is involved in the regulation of cell proliferation and survival.
|
25355291 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we observed the inverse correlation of miR-223 and FBXW7 expression in a panel of T-ALL patient-derived xenografts.
|
24727676 |
2014 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A higher specific hazard of relapse was independently associated with postinduction MRD level ≥10(-4) and unfavorable genetic characteristics (ie, MLL gene rearrangement or focal IKZF1 gene deletion in BCP-ALL and no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN gene alteration in T-cell ALL).
|
24740809 |
2014 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
|
24394663 |
2014 |